The Pharma Data

FEBRUARY 8, 2021

Q4 2020 sales growth (2) of 4.2% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% Diabetes sales, COVID environment and portfolio streamlining. Diabetes sales, COVID environment and portfolio streamlining. Sales down 2.4% Sales down 2.4% Sales increased 3.3%

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

FEBRUARY 4, 2021

Q4 2020 sales growth (2) of 4.2% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% Diabetes sales, COVID environment and portfolio streamlining. Diabetes sales, COVID environment and portfolio streamlining. Sales down 2.4% Sales down 2.4% Sales increased 3.3%

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

OCTOBER 27, 2020

Mirati will not receive any proceeds from the sale of common stock by the selling stockholder. Sitravatinib is an investigational spectrum-selective inhibitor of receptor tyrosine kinases (RTK) designed to enhance immune responses through the inhibition of immunosuppressive signaling. Forward-Looking Statements.

Sales 52

Sales Immune Response Clinical Development Development 52

The Pharma Data

JANUARY 20, 2021

INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Forward-Looking Statements.

DNA 40

DNA Containment Immune Response Sales 40

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. About INOVIO.

DNA 40

DNA Vaccine Vaccination Immune Response 40

The Pharma Data

NOVEMBER 9, 2020

Amgen will record sales in the U.S. and AstraZeneca will record sales in Canada. Amgen will record sales as collaboration revenue. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Outside the U.S.,

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

MAY 16, 2021

KetosisNOW contains clinically relevant amounts of ingredients that fight insulin resistance, inflammation and toxic build up inside the body. You will also see an improvement in your immune. KetosisNOW can help as it targets the problems that cause weight loss resistance. We are confident. weight reduction and fat loss within 30 days.

Production 52

Production Immune Response Insulin Nurses 52

The Pharma Data

OCTOBER 21, 2020

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Gene Therapy 40

Gene Therapy Immune Response Sales Gene 40

The Pharma Data

DECEMBER 21, 2020

Amgen will record sales in the U.S. and AstraZeneca will record sales in Canada. Amgen will record sales as collaboration revenue. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Outside the U.S.,

Trials 40

Trials Production Sales Manufacturing 40

The Pharma Data

JANUARY 31, 2021

Delivery of viral antigens in potent vaccine vectors to elicit a strong immune response is a cornerstone of successful infectious disease vaccines,” said Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone. Locust Walk served as transaction advisor to Gritstone. About Gritstone Oncology.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

Delveinsight

DECEMBER 13, 2020

Vosevi) to treat adult chronic hepatitis C of all genotypes previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor. In July 2017, the US FDA approved sofosbuvir/velpatasvir/voxilaprevir? in January 2019.

Genotype 52

Genotype FDA Approval DNA Drugs 52

The Pharma Data

SEPTEMBER 17, 2020

The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response. billion in R&D and posted sales of CHF 61.5

Antibody 52

Antibody Vaccine Vaccination In-Vitro 52

The Pharma Data

AUGUST 3, 2021

announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. million of revenue associated with the sale of its rights to Cialis ® in China. million of revenue from sales of COVID-19 antibodies.

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

SEPTEMBER 15, 2020

On a non-risk adjusted basis, these opportunities collectively represent more than $15 billion (excluding 20vPnC) in potential incremental revenue for Pfizer from 2020 to 2025, as well as aggregate peak annual sales potential of $35 billion to $40 billion (including 20vPnC).

Vaccine 52

Vaccine Vaccination Gene Therapy Trials 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., did not have antibodies at baseline: seronegative), as prior evidence suggested these patients were at greater risk. futility analysis). .

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. Regeneron has shared these results with the U.S.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

DECEMBER 27, 2020

For example, we have successfully monetized portions of Lineage’s non-core patent portfolio, including through the creation and subsequent sale of businesses like AgeX and OncoCyte, transactions which helped fund our clinical programs without the need for traditional equity financings. Forward-Looking Statements.

Manufacturing 40

Manufacturing Production Development Clinical Trials 40

The Pharma Data

DECEMBER 17, 2020

Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. “The investigational cocktail is now available to indicated high-risk U.S. patients under an Emergency Use Authorization, and we also continue a robust clinical development program.”

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Antibody 40

Antibody Production Clinical Trials Clinical Trials 40

pharmaphorum

AUGUST 13, 2020

Bank of America halted foreclosure sales, evictions and repossessions. One Pfizer brand getting plenty of attention is Xeljanz, their blockbuster anti-JAK rheumatoid arthritis pill that could damp down the massive immune response that overwhelms some COVID-19 patients. AbbVie has donated $1.5

Branding 112

Branding Vaccine Vaccination Filler 112

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. It was recently reported that the addition of an adjuvant to their vaccine led to enhanced immune responses that exceeded responses in convalescent serum from symptomatic COVID-19 patients. According to the Commerce Department, retail sales rose 7.5

Vaccine 92

Vaccine Vaccination Antibody Life Science 92